Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 10.72 is in line with its 5-year average of 10.39, around the middle of its 5-year range (7.93–13.09).
As of the fiscal period ended Tuesday, June 30, 2026. 18.01% above its 12-month average of 9.08.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.72.
QUICK RATIO (ACID-TEST)
10.72
QUICK RATIO (ACID-TEST) AVG TTM
9.08
QUICK RATIO (ACID-TEST) AVG 3Y
10.17
QUICK RATIO (ACID-TEST) AVG 5Y
10.39
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.01%
CURRENT VS 3Y AVG
+5.35%
CURRENT VS 5Y AVG
+3.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.92
median of 460 covered companies
CURRENT VS SECTOR MEDIAN
+267.00%
vs the sector median at left
Allogene Therapeutics, Inc.
Market Cap
$517.73M
Quick Ratio (Acid-Test)
10.72
TTM Avg
9.08
3Y Avg
10.17
5Y Avg
10.39
Market Cap
$517.79M
Quick Ratio (Acid-Test)
9.66
TTM Avg
5.09
3Y Avg
5.58
5Y Avg
6.85
Market Cap
$519.25M
Quick Ratio (Acid-Test)
26.78
TTM Avg
15.83
3Y Avg
15.06
5Y Avg
15.09
Market Cap
$491.55M
Quick Ratio (Acid-Test)
3.35
TTM Avg
2.92
3Y Avg
4.56
5Y Avg
5.25
Market Cap
$547.86M
Quick Ratio (Acid-Test)
8.95
TTM Avg
10.43
3Y Avg
5.97
5Y Avg
5.34
Market Cap
$487.30M
Quick Ratio (Acid-Test)
121.97
TTM Avg
23.71
3Y Avg
19.95
5Y Avg
19.50
Market Cap
$551.09M
Quick Ratio (Acid-Test)
25.13
TTM Avg
6.17
3Y Avg
7.34
5Y Avg
19.91
Market Cap
$481.33M
Quick Ratio (Acid-Test)
7.91
TTM Avg
4.78
3Y Avg
4.69
5Y Avg
6.49
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $517.73M | 10.72 | 9.08 | 10.17 | 10.39 |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | 9.66 | 5.09 | 5.58 | 6.85 |
| Altimmune, Inc. (ALT)vs › | $519.25M | 26.78 | 15.83 | 15.06 | 15.09 |
| Evolus, Inc. (EOLS)vs › | $491.93M | 1.28 | 1.88 | 1.90 | 1.89 |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | 3.35 | 2.92 | 4.56 | 5.25 |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 8.95 | 10.43 | 5.97 | 5.34 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | 121.97 | 23.71 | 19.95 | 19.50 |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | 25.13 | 6.17 | 7.34 | 19.91 |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 7.91 | 4.78 | 4.69 | 6.49 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | 37.17 | 24.09 | 19.47 | 19.38 |
Quick Ratio
10.72
Excludes inventory
Current Ratio
10.72
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 10.72 |
| 2026-03-31 | 9.65 |
| 2025-12-31 | 7.93 |
| 2025-09-30 | 8.19 |
| 2025-06-30 | 8.92 |
| 2025-03-31 | 9.71 |
| 2024-12-31 | 8.54 |
| 2024-09-30 | 9.35 |
| 2024-06-30 | 12.25 |
| 2024-03-31 | 12.80 |
| 2023-12-31 | 12.38 |
| 2023-09-30 | 12.62 |
| 2023-06-30 | 9.18 |
| 2023-03-31 | 8.08 |
| 2022-12-31 | 9.84 |
| 2022-09-30 | 11.64 |
| 2022-06-30 | 11.42 |
| 2022-03-31 | 12.74 |
| 2021-12-31 | 9.84 |
| 2021-09-30 | 9.40 |
| 2021-06-30 | 13.09 |
| 2021-03-31 | 13.06 |
| 2020-12-31 | 8.96 |
| 2020-09-30 | 17.04 |
| 2020-06-30 | 22.24 |
| 2020-03-31 | 18.81 |
| 2019-12-31 | 16.46 |
| 2019-09-30 | 15.28 |
| 2019-06-30 | 17.35 |
| 2019-03-31 | 17.48 |
| 2018-12-31 | 24.78 |
| 2018-09-30 | 1.55 |
| 2018-06-30 | 19.96 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
